bremelanotide vs setmelanotide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: MC4R · full Obesity pipeline
bremelanotide · Vyleesi
Marketed by Cosette Pharmaceuticals and partners
NCT06565611 · Phase 2 · active, not recruiting
This was a randomized, triple-blinded, placebo-controlled Phase 2 study using percent body weight change -- an objective, disease-defining measure accepted for obesity drug approval -- as its primary endpoint. According to a sourced result reported outside the registry, the bremelanotide/tirzepatide combination arm significantly outperformed placebo (4.4% vs 1.6% weight loss, p<0.0001), meeting the primary endpoint with strong statistical significance.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. The sponsor reports 113 patients enrolled and 96 randomised 3:1; the registry's 108 is its estimated enrolment.
Reported efficacy
Percent change in body weight between treatment arms (Change from the baseline (Visit 2/Day 1) to Visit 10 (Day 57)): BMT-801 study (NCT06565611): weight reduction 4.4% (bremelanotide + tirzepatide) vs 1.6% (placebo); p<0.0001. (met)
Result source: NCT06565611
setmelanotide · Imcivree
Marketed by Rhythm Pharmaceuticals
NCT02896192 · Phase 3 · completed
The study was an open-label, single-group trial of 15 participants; although it included a short double-blind placebo-withdrawal period, the primary one-year weight-loss endpoint was assessed without a parallel placebo or active-control arm. The primary endpoint was statistically positive against a predefined 5% benchmark, but the uncontrolled design limits the strength of evidence.
Next expected readout: March 2027 · NCT06760546 (registry estimate)
Reported efficacy
Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen (Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)): Pivotal Cohort: Mean Percent Change From Baseline in Body Mass Index (BMI) After 52 Weeks on a Therapeutic Regimen (Baseline, after approximately 52 Weeks on a Therapeutic Regimen (up to approximately 60 weeks)): Setmelanotide -16.51 Percent change (Standard Error 1.401) | Placebo 3.32 Percent change (Standard Error 1.984) (met)
Result source: NCT05774756
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | bremelanotide | setmelanotide |
|---|---|---|
| Body weight, % change | —Not reported | 0.4% vs -0.4%+0.8 vs placeboNCT0231167320 other results
|
| Weight loss of 5% or more | —Not reported | 9.1% vs 5.6%+3.5 vs placeboNCT017491371 other result
|
| Weight loss of 10% or more | —Not reported | —Not posted · NCT06596135 |
| Waist circumference, change (cm) | —Not reported | —Not posted · NCT06596135 |
Body weight, % change
- bremelanotide
- —Not reported
- setmelanotide
- 0.4% vs -0.4%+0.8 vs placeboNCT02311673
20 other results
- -2.3% vs -0.1% NCT02041195
- -0.8% vs -0.4% NCT02311673
- -2% vs -0.3% NCT01749137
- -0.7% vs 2.9% NCT02041195
- -1.3% vs 2.3% NCT02041195
- -1.4% vs 2.9% NCT02041195
- -0.7% vs -0.4% NCT02311673
- 0% vs 0.2% NCT02311673
- 0.9% vs -1% NCT02311673
- 0.7% vs -0.7% NCT02311673
- -0.3% vs -0.9% NCT02311673
- 0% vs 0.2% NCT02311673
- -0.4% vs -1% NCT02311673
- -0.5% vs -0.7% NCT02311673
- -1.1% vs -0.9% NCT02311673
- -2.3% vs -0.7% NCT01749137
- 1.3% vs 0.2% NCT02311673
- 0.2% vs -1% NCT02311673
- -0.7% vs -0.7% NCT02311673
- -0.2% vs -0.9% NCT02311673
Weight loss of 5% or more
- bremelanotide
- —Not reported
- setmelanotide
- 9.1% vs 5.6%+3.5 vs placeboNCT01749137
1 other result
- 11.8% vs 11.8% NCT01749137
Weight loss of 10% or more
- bremelanotide
- —Not reported
- setmelanotide
- —Not posted · NCT06596135
Waist circumference, change (cm)
- bremelanotide
- —Not reported
- setmelanotide
- —Not posted · NCT06596135
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. bremelanotide: 0 of 4 rows · setmelanotide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | setmelanotide |
|---|---|
| Dropout rate | 0%a NCT02896192 · Phase 3 · monotherapy · Obesity · phase 3 show 35 more results0% NCT03287960 · Phase 3 · monotherapy · Obesity · phase 3 —Setmelanotide (Double-Blind Period NCT03746522 · Phase 3 —Setmelanotide (Open-label) NCT03746522 · Phase 3 0%Setmelanotide: BBS Group NCT04966741 · Phase 3 14.3%Setmelanotide: PPL Group NCT04966741 · Phase 3 56.6% NCT03651765 · Phase 2/3 · registry result, not featured evidence 39%Stage 1: Setmelanotide (Open-Label NCT04963231 · Phase 2 · registry result, not featured evidence —Stage 2: Setmelanotide (Double-Bli NCT04963231 · Phase 2 · registry result, not featured evidence 11.1% NCT04725240 · Phase 2 · registry result, not featured evidence 0%16p11.2 Cohort NCT03013543 · Phase 2 · registry result, not featured evidence 50%AS Cohort NCT03013543 · Phase 2 · registry result, not featured evidence 30%BBS Cohort NCT03013543 · Phase 2 · registry result, not featured evidence 24.5%MC4R Cohort NCT03013543 · Phase 2 · registry result, not featured evidence 60%POMC/PCSK1/LEPR Composite Heterozy NCT03013543 · Phase 2 · registry result, not featured evidence 25.9%POMC/PCSK1/LEPR Compound Heterozyg NCT03013543 · Phase 2 · registry result, not featured evidence 33.3%POMC/PCSK1/LEPR Heterozygous Cohor NCT03013543 · Phase 2 · registry result, not featured evidence 40.9%SH2B1 Cohort NCT03013543 · Phase 2 · registry result, not featured evidence 25%SMS Cohort NCT03013543 · Phase 2 · registry result, not featured evidence 31.3%SRC1 Cohort NCT03013543 · Phase 2 · registry result, not featured evidence —2.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence —2.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence —2.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence —2.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence —1.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence —1.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence —1.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence —1.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence —0.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence —0.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence —0.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence 40.5% NCT01749137 · Phase 2 · registry result, not featured evidence 24.1%2 mg QD NCT02041195 · Phase 1/2 · registry result, not featured evidence 33.3%1.5 mg QD NCT02041195 · Phase 1/2 · registry result, not featured evidence 9.1%1.5 mg QD NCT02041195 · Phase 1/2 · registry result, not featured evidence 20%0.75 mg BID NCT02041195 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT02896192 · Phase 3 · monotherapy · Obesity · phase 3 show 35 more results— NCT03287960 · Phase 3 · monotherapy · Obesity · phase 3 —Setmelanotide (Double-Blind Period NCT03746522 · Phase 3 —Setmelanotide (Open-label) NCT03746522 · Phase 3 —Setmelanotide: BBS Group NCT04966741 · Phase 3 —Setmelanotide: PPL Group NCT04966741 · Phase 3 2.9% NCT03651765 · Phase 2/3 · registry result, not featured evidence 26.2%Stage 1: Setmelanotide (Open-Label NCT04963231 · Phase 2 · registry result, not featured evidence —Stage 2: Setmelanotide (Double-Bli NCT04963231 · Phase 2 · registry result, not featured evidence 11.1% NCT04725240 · Phase 2 · registry result, not featured evidence 0%16p11.2 Cohort NCT03013543 · Phase 2 · registry result, not featured evidence 0%AS Cohort NCT03013543 · Phase 2 · registry result, not featured evidence 0%BBS Cohort NCT03013543 · Phase 2 · registry result, not featured evidence 6.1%MC4R Cohort NCT03013543 · Phase 2 · registry result, not featured evidence 20%POMC/PCSK1/LEPR Composite Heterozy NCT03013543 · Phase 2 · registry result, not featured evidence 11.1%POMC/PCSK1/LEPR Compound Heterozyg NCT03013543 · Phase 2 · registry result, not featured evidence 6.1%POMC/PCSK1/LEPR Heterozygous Cohor NCT03013543 · Phase 2 · registry result, not featured evidence 36.4%SH2B1 Cohort NCT03013543 · Phase 2 · registry result, not featured evidence 0%SMS Cohort NCT03013543 · Phase 2 · registry result, not featured evidence 6.3%SRC1 Cohort NCT03013543 · Phase 2 · registry result, not featured evidence —2.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence —2.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence —2.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence —2.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence —1.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence —1.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence —1.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence —1.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence —0.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence —0.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence —0.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence 10.8% NCT01749137 · Phase 2 · registry result, not featured evidence 10.3%2 mg QD NCT02041195 · Phase 1/2 · registry result, not featured evidence 22.2%1.5 mg QD NCT02041195 · Phase 1/2 · registry result, not featured evidence 0%1.5 mg QD NCT02041195 · Phase 1/2 · registry result, not featured evidence 10%0.75 mg BID NCT02041195 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 40%a NCT02896192 · Phase 3 · monotherapy · Obesity · phase 3 show 35 more results20% NCT03287960 · Phase 3 · monotherapy · Obesity · phase 3 3.7%Setmelanotide (Double-Blind Period NCT03746522 · Phase 3 0%Setmelanotide (Open-label) NCT03746522 · Phase 3 0%Setmelanotide: BBS Group NCT04966741 · Phase 3 0%Setmelanotide: PPL Group NCT04966741 · Phase 3 13.2% NCT03651765 · Phase 2/3 · registry result, not featured evidence 3.7%Stage 1: Setmelanotide (Open-Label NCT04963231 · Phase 2 · registry result, not featured evidence 0%Stage 2: Setmelanotide (Double-Bli NCT04963231 · Phase 2 · registry result, not featured evidence 5.6% NCT04725240 · Phase 2 · registry result, not featured evidence 5.3%16p11.2 Cohort NCT03013543 · Phase 2 · registry result, not featured evidence 0%AS Cohort NCT03013543 · Phase 2 · registry result, not featured evidence 10%BBS Cohort NCT03013543 · Phase 2 · registry result, not featured evidence 2%MC4R Cohort NCT03013543 · Phase 2 · registry result, not featured evidence 20%POMC/PCSK1/LEPR Composite Heterozy NCT03013543 · Phase 2 · registry result, not featured evidence 7.4%POMC/PCSK1/LEPR Compound Heterozyg NCT03013543 · Phase 2 · registry result, not featured evidence 3%POMC/PCSK1/LEPR Heterozygous Cohor NCT03013543 · Phase 2 · registry result, not featured evidence 0%SH2B1 Cohort NCT03013543 · Phase 2 · registry result, not featured evidence 0%SMS Cohort NCT03013543 · Phase 2 · registry result, not featured evidence 0%SRC1 Cohort NCT03013543 · Phase 2 · registry result, not featured evidence —2.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence 0%2.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence 0%2.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence 0%2.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence —1.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence 0%1.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence 0%1.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence 0%1.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence —0.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence 0%0.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence 0%0.5 mg NCT02311673 · Phase 2 · registry result, not featured evidence 0% NCT01749137 · Phase 2 · registry result, not featured evidence 3.4%2 mg QD NCT02041195 · Phase 1/2 · registry result, not featured evidence 0%1.5 mg QD NCT02041195 · Phase 1/2 · registry result, not featured evidence 0%1.5 mg QD NCT02041195 · Phase 1/2 · registry result, not featured evidence 0%0.75 mg BID NCT02041195 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | a skin hyperpigmentation 100% injection site erythema 80% injection site oedema 60% NCT02896192 · Phase 3 · monotherapy · Obesity · phase 3 show 32 more resultsinjection site erythema 73.3% skin hyperpigmentation 73.3% injection site pruritus 53.3% NCT03287960 · Phase 3 · monotherapy · Obesity · phase 3 skin hyperpigmentation 63% (placebo 0%) injection site erythema 44.4% (placebo 44%) injection site pruritus 29.6% (placebo 36%) NCT03746522 · Phase 3 skin hyperpigmentation 38% (placebo 0%) nausea 16% (placebo 24%) vomiting 16% (placebo 0%) NCT03746522 · Phase 3 skin hyperpigmentation 80% injection site bruising 60% injection site pruritus 60% NCT04966741 · Phase 3 skin hyperpigmentation 53.7% covid-19 29.3% headache 29.3% NCT03651765 · Phase 2/3 · registry result, not featured evidence skin hyperpigmentation 79.3% (placebo 7.1%) nausea 45.7% (placebo 0%) injection site erythema 37.8% (placebo 14.3%) NCT04963231 · Phase 2 · registry result, not featured evidence melanocytic naevus 20% (placebo 14.3%) skin hyperpigmentation 20% (placebo 7.1%) headache 11.4% (placebo 0%) NCT04963231 · Phase 2 · registry result, not featured evidence nausea 61.1% skin hyperpigmentation 33.3% vomiting 33.3% NCT04725240 · Phase 2 · registry result, not featured evidence skin hyperpigmentation 89.5% headache 47.4% nausea 47.4% NCT03013543 · Phase 2 · registry result, not featured evidence skin hyperpigmentation 75% injection site pruritus 50% viral upper respiratory tract infection 50% NCT03013543 · Phase 2 · registry result, not featured evidence injection site pruritus 90% skin hyperpigmentation 80% injection site oedema 70% NCT03013543 · Phase 2 · registry result, not featured evidence skin hyperpigmentation 81.6% melanocytic naevus 28.6% nausea 24.5% NCT03013543 · Phase 2 · registry result, not featured evidence nausea 80% skin hyperpigmentation 60% injection site erythema 40% NCT03013543 · Phase 2 · registry result, not featured evidence skin hyperpigmentation 77.8% headache 48.1% nausea 48.1% NCT03013543 · Phase 2 · registry result, not featured evidence skin hyperpigmentation 57.6% nausea 42.4% fatigue 33.3% NCT03013543 · Phase 2 · registry result, not featured evidence skin hyperpigmentation 72.7% nausea 59.1% headache 45.5% NCT03013543 · Phase 2 · registry result, not featured evidence skin hyperpigmentation 83.3% diarrhoea 33.3% macule 25% NCT03013543 · Phase 2 · registry result, not featured evidence skin hyperpigmentation 71.9% nausea 34.4% melanocytic naevus 25% NCT03013543 · Phase 2 · registry result, not featured evidence 2.5 mg injection site erythema 50% (placebo 40%) injection site induration 25% (placebo 20%) blood creatine phosphokinase increased 12.5% (placebo 0%) NCT02311673 · Phase 2 · registry result, not featured evidence 2.5 mg injection site erythema 37.5% (placebo 40%) injection site induration 37.5% (placebo 20%) injection site discolouration 12.5% (placebo 0%) NCT02311673 · Phase 2 · registry result, not featured evidence 2.5 mg injection site erythema 80% (placebo 40%) abnormal behaviour 0% (placebo 0%) aggression 0% (placebo 0%) NCT02311673 · Phase 2 · registry result, not featured evidence 1.5 mg injection site erythema 38.5% (placebo 40%) injection site induration 30.8% (placebo 20%) injection site pruritus 23.1% (placebo 6.7%) NCT02311673 · Phase 2 · registry result, not featured evidence 1.5 mg injection site erythema 36.4% (placebo 40%) injection site induration 27.3% (placebo 20%) injection site oedema 27.3% (placebo 13.3%) NCT02311673 · Phase 2 · registry result, not featured evidence 1.5 mg injection site erythema 40% (placebo 40%) injection site induration 20% (placebo 20%) injection site oedema 20% (placebo 13.3%) NCT02311673 · Phase 2 · registry result, not featured evidence 0.5 mg injection site bruising 75% (placebo 20%) injection site erythema 75% (placebo 40%) headache 50% (placebo 0%) NCT02311673 · Phase 2 · registry result, not featured evidence 0.5 mg injection site erythema 66.7% (placebo 40%) injection site induration 66.7% (placebo 20%) injection site bruising 33.3% (placebo 20%) NCT02311673 · Phase 2 · registry result, not featured evidence skin hyperpigmentation 24.3% (placebo 0%) application site pruritus 13.5% (placebo 2.7%) nausea 13.5% (placebo 8.1%) NCT01749137 · Phase 2 · registry result, not featured evidence 2 mg QD skin hyperpigmentation 89.7% (placebo 33.3%) nausea 58.6% (placebo 0%) headache 55.2% (placebo 0%) NCT02041195 · Phase 1/2 · registry result, not featured evidence 1.5 mg QD nausea 66.7% (placebo 0%) skin hyperpigmentation 66.7% (placebo 33.3%) headache 44.4% (placebo 0%) NCT02041195 · Phase 1/2 · registry result, not featured evidence 1.5 mg QD skin hyperpigmentation 72.7% (placebo 33.3%) nausea 54.5% (placebo 0%) headache 36.4% (placebo 0%) NCT02041195 · Phase 1/2 · registry result, not featured evidence 0.75 mg BID skin hyperpigmentation 70% (placebo 33.3%) headache 50% (placebo 0%) injection site pruritus 40% (placebo 0%) NCT02041195 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 34 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
setmelanotide
show 1 more result
show 13 more results
show 1 more result
show 2 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 11 more results
+ 32 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: bremelanotide's landscape · setmelanotide's landscape